» Articles » PMID: 3262237

Effects of Cyclosporine A on T Cell Development and Clonal Deletion

Overview
Journal Science
Specialty Science
Date 1988 Sep 23
PMID 3262237
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclosporine A (CsA) is an important immunosuppressive drug that is widely used in transplantation medicine. Many of its suppressive effects on T cells appear to be related to the inhibition of T cell receptor (TCR)-mediated activation events. Paradoxically, in certain situations CsA is responsible for the induction of a T cell-mediated autoimmunity. The effects of CsA on T cell development in the thymus were investigated to elucidate the physiologic events underlying this phenomenon. Two major effects were revealed: (i) CsA inhibits the development of mature single positive (CD4+8- or CD4-8+) TCR-alpha beta+ thymocytes without discernibly affecting CD4-8- TCR-gamma delta+ thymocytes and (ii) CsA interferes with the deletion of cells bearing self-reactive TCRs in the population of single positive thymocytes that do develop. This suggests a direct mechanism for CsA-induced autoimmunity and may have implications for the relative contribution of TCR-mediated signaling events in the development of the various T cell lineages.

Citing Articles

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.

Cui S, Li L, Liu W, Zhao B, Zhong X Braz J Med Biol Res. 2024; 57:e13392.

PMID: 39082578 PMC: 11290814. DOI: 10.1590/1414-431X2024e13392.


Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD.

Wang Y, Ullah M, Waltner O, Bhise S, Ensbey K, Schmidt C J Clin Invest. 2024; 134(11).

PMID: 38828727 PMC: 11142741. DOI: 10.1172/JCI170125.


A Novel Combination of Compound Heterozygous Variants in IFNGR1 Causing Complete IFNGR1 Deficiency.

LaBere B, Christian E, Kapadia M, Prockop S, McDonald D, Johnston A J Clin Immunol. 2024; 44(5):111.

PMID: 38676746 DOI: 10.1007/s10875-024-01716-7.


Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.

Nguyen T, Kim Y, Jeong G, Jin M Exp Mol Med. 2024; 56(3):559-569.

PMID: 38448692 PMC: 10984945. DOI: 10.1038/s12276-024-01182-6.


Mass cytometric analysis unveils a disease-specific immune cell network in the bone marrow in acquired aplastic anemia.

Pool E, Kooy-Winkelaar Y, van Unen V, Falkenburg J, Koning F, Heemskerk M Front Immunol. 2023; 14:1274116.

PMID: 38094307 PMC: 10716190. DOI: 10.3389/fimmu.2023.1274116.